Tonix Pharmaceuticals (US:TNXP) Globenewswire·2025-10-21 11:00Core Insights - Tonix Pharmaceuticals Holding Corp. announced a poster presentation for Tonmya™ (cyclobenzaprine HCl sublingual tablets) at the 2025 American College of Rheumatology Convergence, highlighting its efficacy in pain reduction and tolerability for fibromyalgia patients [1][3]. Company Overview - Tonix Pharmaceuticals is a fully-integrated biotechnology company with marketed products and a pipeline focused on central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases [3]. - The company has received FDA approval for Tonmya™, marking the first new prescription medicine for fibromyalgia in over 15 years [3]. - Tonix also markets two treatments for acute migraine in adults and is developing TNX-102 SL for acute stress reaction, major depressive disorder, and other conditions [3]. Product Development - Tonmya™ is indicated for the treatment of fibromyalgia in adults and is a first-in-class, non-opioid analgesic [3][7]. - The company is developing TNX-1500, an Fc-modified humanized monoclonal antibody for organ transplant rejection and autoimmune diseases [3]. - Tonix's infectious disease portfolio includes TNX-801, a vaccine for mpox and smallpox, and TNX-4800, a monoclonal antibody for Lyme Disease prevention [3]. Clinical Presentation - The poster presentation titled "TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Participants With Fibromyalgia" will take place on October 27, 2025, in Chicago, Illinois [3].